Role of LMO1 in Neuroblastoma Initiation and Maintenance
Role of LMO1 in Neuroblastoma Initiation and Maintenance
批准号:
9238724
负责人:
A. THOMAS LOOK
金额:
$60.68万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-01 至 2020-03-31
关键词:
AddressAdvanced DevelopmentBinding SitesBiological AssayBiological ModelsCell modelCellsCessation of lifeCharacteristicsChildClonal EvolutionComplementDNADNA ResequencingDataDependenceDevelopmentDiseaseDissectionDoxycyclineEnhancersEpigenetic ProcessEventGenesGeneticGenetic DeterminismGenetic Enhancer ElementGenetic PolymorphismGenetic TranscriptionGoalsGrowthHealthHeritabilityHumanInheritedIntronsInvestigationLIM DomainLaboratoriesLeadershipMYCN geneMaintenanceMalignant - descriptorMalignant Childhood NeoplasmMalignant NeoplasmsMediatingMethodsMissionModelingMolecularMolecular TargetMutationNeuroblastomaOncogenesOncogenicOutcomePathway interactionsPenetrancePeripheralPhenotypePredispositionPrincipal InvestigatorProteinsPublic HealthPublishingRecurrenceRegulatory ElementReporterResearchResearch Project GrantsResourcesRoleSingle Nucleotide PolymorphismSiteSomatic MutationSusceptibility GeneSympathetic Nervous SystemSystems DevelopmentTestingTherapeuticTissuesTransgenic OrganismsTreatment FailureUnited States National Institutes of HealthUp-RegulationValidationVariantWorkZebrafishanticancer researchbasecancer genomecancer initiationcell growthchemotherapychildhood cancer mortalityclinically relevantcofactordesignevidence basefunctional genomicsgenetic approachgenetic associationgenome editinggenome wide association studyhigh riskhuman diseasein vivoinduced pluripotent stem cellinnovationinsightmalignant phenotypemolecular subtypesneoplastic cellneuroblastoma cellnovelnovel therapeuticsoverexpressionpersonalized therapeuticprogramspublic health relevanceself-renewalskillstargeted treatmenttranscription factortumortumor DNAtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving greatly intensified chemotherapy, underscoring the need to design novel molecular therapies for this disease, which constitutes the long-term goal of our proposal. However, recent efforts to discover promising molecular targets in this aggressive pediatric malignancy have revealed a very low somatic mutation rate, and the majority of high-risk tumors do not harbor druggable oncogenic proteins activated by somatic mutations, demonstrating that personalized therapeutic strategies will require insights well beyond those afforded by resequencing tumor DNA alone. This multiple principal investigator project will build on our recent genome- wide association study (GWAS) discovery of a robust genetic association at the LMO1 gene locus, which encodes a LIM-domain-only (LMO) transcriptional cofactor. Together, our published and unpublished preliminary data support a major oncogenic role for LMO1 in the most aggressive subset of neuroblastomas, and suggest the following central hypothesis: LMO1 is required for the initiation and maintenance of the malignant phenotype in a substantial subset of high-risk neuroblastoma cases. We propose to test this original concept in two integrated Specific Aims using the multi-PI leadership mechanism to bring together complementary research skills and resources available in the Maris and Look laboratories. In Aim 1, we will focus on how polymorphisms at the LMO1 locus alter regulatory mechanisms of the LMO1 gene in developing sympathetic nervous system cells to promote the initiation of neuroblastoma using genetic and epigenetic approaches in human-derived tissues and genome editing in the zebrafish model system. In Aim 2, we will focus on the mechanism by which LMO1 overexpression is somatically deregulated during malignant neuroblastic clonal evolution, and will seek to discover the key cellular networks that maintain the highly proliferative and metastatic phenotype characteristic of neuroblastomas high levels of LMO1 expression. The innovation of this project resides in the combined use of robust human (epi)genetic approaches with a novel and highly manipulable zebrafish model of neuroblastoma to address a fundamental problem with high clinical relevance. Our results will establish the requirement for LMO1 in neuroblastoma initiation, growth and survival. The work proposed here will serve as a roadmap for the investigation of GWAS discoveries in cancer and other human diseases, providing a paradigm for determining their mechanistic and clinical relevance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
-
批准号:9341186
-
项目类别:
-
资助金额:$104.64万
-
财政年份:2016
-
负责人:A. THOMAS LOOK
-
依托单位:
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
-
批准号:10238895
-
项目类别:
-
资助金额:$104.64万
-
财政年份:2016
-
负责人:A. THOMAS LOOK
-
依托单位:
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
-
批准号:10004576
-
项目类别:
-
资助金额:$104.64万
-
财政年份:2016
-
负责人:A. THOMAS LOOK
-
依托单位:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
-
批准号:9452737
-
项目类别:
-
资助金额:$60.68万
-
财政年份:2015
-
负责人:A. THOMAS LOOK
-
依托单位:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
-
批准号:9032459
-
项目类别:
-
资助金额:$60.68万
-
财政年份:2015
-
负责人:A. THOMAS LOOK
-
依托单位:
Role of LMO1 in Neuroblastoma Initiation and Maintenance
-
批准号:8888225
-
项目类别:
-
资助金额:$62.38万
-
财政年份:2015
-
负责人:A. THOMAS LOOK
-
依托单位:
Leukemia
-
批准号:8533073
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Discovery of New Targets and Pathways for T-ALL Therapy
-
批准号:8710114
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Discovery of New Targets and Pathways for T-ALL Therapy
-
批准号:8901763
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Discovery of New Targets and Pathways for T-ALL Therapy
-
批准号:8550035
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Leukemia
-
批准号:8606540
-
项目类别:
-
资助金额:$11.45万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Leukemia
-
批准号:8533072
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Discovery of New Targets and Pathways for T-ALL Therapy
-
批准号:8514755
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Leukemia
-
批准号:8710588
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2012
-
负责人:A. THOMAS LOOK
-
依托单位:
Administrative Core
-
批准号:7780953
-
项目类别:
-
资助金额:$5.35万
-
财政年份:2010
-
负责人:A. THOMAS LOOK
-
依托单位:
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy
-
批准号:7780946
-
项目类别:
-
资助金额:$60.44万
-
财政年份:2010
-
负责人:A. THOMAS LOOK
-
依托单位:
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2
-
批准号:7811055
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2009
-
负责人:A. THOMAS LOOK
-
依托单位:
Synthetic Lethal Targeting of p53 in Myelodysplasia
-
批准号:8092579
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2007
-
负责人:A. THOMAS LOOK
-
依托单位:
Synthetic Lethal Targeting of p53 in Myelodysplasia
-
批准号:7251375
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2007
-
负责人:A. THOMAS LOOK
-
依托单位:
Synthetic Lethal Targeting of p53 in Myelodysplasia
-
批准号:7858453
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2007
-
负责人:A. THOMAS LOOK
-
依托单位:
海外基金